Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study

Abstract Background Pre-clinical data suggests a potential synergistic effect of eribulin and platinum. However, clinical data on the combination for metastatic breast cancer (mBC) is lacking. We evaluated the efficacy and safety of eribulin plus carboplatin (ErCb) in patients with mBC. Patients and...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Mengqian Ni, Lijia Zhou, Yongkui Lu, Dachuan Guo, Xiuyue Li, Lixia Li, Lidong Zhang, Meiting Chen, Lulu Zhang, Fei Xu, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Anli Yang, Xin An
Format:	Article
Language:	English
Published:	BMC 2024-09-01
Subjects:	Metastatic breast cancer Eribulin Carboplatin Efficacy Safety
Online Access:	https://doi.org/10.1186/s12885-024-12953-9